chloroquine phosphate

ApprovedSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

chloroquine phosphate is one of 148 small molecule programs targeting Malaria. It is currently in Approved.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

PneumoniaActive, not recruiting

ImmunodeficiencyActive, not recruiting

Atrial FibrillationActive, not recruiting

COVID-19Active, not recruiting

Pancreatic Cancer MetastaticTerminated

MalariaApproved

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

ImmunodeficiencyPhase 2/Phase 3

Active, not recruiting

Atrial FibrillationPhase 2

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Pancreatic Cancer MetastaticPhase 1

Terminated

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

chloroquine phosphate

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

2 2

Spikevax

Moderna

Preclinical

21 3

Biaxin

AbbVie

Preclinical

2 4

Aimovig

Amgen

Preclinical

1 5

Aldactone

Pfizer

Preclinical

1 6

Nexavar

Bayer

Preclinical

1 7

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 8

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 9

Rayaldee

OOrganon and Co

Preclinical

1 10

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-192 trials

The Vietnam Chloroquine Treatment on COVID-19

Completed·OOxford University Clinical Research Unit, Vietnam·Phase 2·NCT04328493·10 enrolled

Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients

Unknown status·CCMN "20 de Noviembre"·Phase 1·NCT04443270·200 enrolled

Malaria2 trials

Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug

Completed·—·Phase 1·NCT01366235·10 enrolled

Effectiveness of Malaria Treatment in Mexico

Completed·LLILIA GONZALEZ CERON·Phase 4·NCT02394197·153 enrolled

Immunodeficiency1 trial

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

Terminated·UUniversity of Minnesota·Phase 2/3·NCT00308620·13 enrolled

Atrial Fibrillation1 trial

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Recruiting·UUniversity of South Florida·Phase 2·NCT02932007·40 enrolled

Vaccination1 trial

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03952650·252 enrolled

4 more indications

Pneumonia1 trial

Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia

Withdrawn·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT04428268

Corona Virus Infection1 trial

Chloroquine as Antiviral Treatment in Coronavirus Infection 2020

Completed·WWroclaw Medical University·Phase 4·NCT04331600·16 enrolled

Pancreatic Cancer Metastatic1 trial

An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer

Terminated·HHonorHealth Research Institute·Phase 1·NCT06076837·6 enrolled

Unspecified1 trial

Dose Escalation PfSPZ-CVac

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03083847·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for chloroquine phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chloroquine phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chloroquine phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

chloroquine phosphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-192 trials

Malaria2 trials

Immunodeficiency1 trial

Atrial Fibrillation1 trial

Vaccination1 trial

Pneumonia1 trial

Corona Virus Infection1 trial

Pancreatic Cancer Metastatic1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News